GLP-1 Receptor Agonists Demonstrate Broad Anti-Cancer Potential
Glucagon-like peptide-1 receptor agonists may enhance several aspects of cancer treatment, according to five real-world studies that will be…
-
-
The Role of Oral and Reduced-Dose GLP-1 Medications in Weight Maintenance
Obesity treatment has entered a critical new phase. Injectable medications like semaglutide and tirzepatide now achieve weight loss between…
-
GLP-1 Receptor Agonists and Bile Acid Malabsorption: Emerging Evidence and Mechanisms
Bile acid malabsorption affects about 1% of the general population. This condition causes chronic and socially difficult symptoms. Patients…
-
Oura Ring 5 Launches With Blood Pressure Monitoring and GLP-1 Medication Tracking
Oura recently unveiled the Oura Ring 5. This redesigned wearable introduces clinical features within a significantly reduced form factor….
-
GLP-1 Receptor Agonists Linked to Greater Physical Activity in MS; BLA Filed for Z-Rostudirsen; Ofatumumab Shows Superiority Over Rituximab in MOGAD
New data presented at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting indicate that glucagon-like peptide-1 receptor agonists…
-
Protecting Muscle Mass While Using GLP-1 Medications: A Nutrition Guide
New medications for weight loss have changed how we treat obesity and type 2 diabetes. These drugs, known as…
-
Next-Generation GLP-1 Drugs Deliver Surgical-Level Weight Loss, Raising Questions About Systemic Safety
Retatrutide acts as a new kind of experimental medicine. This drug helped people lose over 28 percent of their…
-
GLP-1 Drug Users Show Reduced Risk of Disease After Weight Loss, Study Reports
Obesity currently affects more than 40 per cent of adults. This condition drives high rates of heart disease and…
-
Online Pharmacy Criticized for Aggressive Black Friday GLP-1 Advertising
A national advertising watchdog has issued a formal ruling against a prominent online pharmacy for its holiday marketing of…
-
Study: GLP-1 Drugs Used for Weight Loss Could Help Prevent Cancer Growth
These days, GLP-1 receptor agonists are changing how type 2 diabetes and obesity are treated clinically. These therapeutic compounds…
